PIM inhibition was shown to downregulate the MYC transcriptional program in DLBCL cells, further suggesting that PIM recovery following CDK9i observed in our study may contribute to therapeutic resistance [46]. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.